Pathophysiology of the heart in Chagas' disease: current status and new developments.
about
Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infectionPharmacological interventions for treating heart failure in patients with Chagas cardiomyopathyPharmacological interventions for treating heart failure in patients with Chagas cardiomyopathyComparative analysis of the kinomes of three pathogenic trypanosomatids: Leishmania major, Trypanosoma brucei and Trypanosoma cruzi.Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathyTreatment of Chagas cardiomyopathyCurrent understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas diseaseAptamer-based detection of disease biomarkers in mouse models for chagas drug discoveryPentoxifylline reverses chronic experimental Chagasic cardiomyopathy in association with repositioning of abnormal CD8+ T-cell responseEvaluation of Parasiticide Treatment with Benznidazol in the Electrocardiographic, Clinical, and Serological Evolution of Chagas DiseaseDifferential Gel Electrophoresis (DIGE) Evaluation of Naphthoimidazoles Mode of Action: A Study in Trypanosoma cruzi Bloodstream TrypomastigotesEnhanced nitrosative stress during Trypanosoma cruzi infection causes nitrotyrosine modification of host proteins: implications in Chagas' disease.Chagas cardiomyopathy in the context of the chronic disease transition.Etanercept induces low QRS voltage and autonomic dysfunction in mice with experimental Chagas disease.Transcriptomic signatures of alterations in a myoblast cell line infected with four distinct strains of Trypanosoma cruzi.Nutritional Status Driving Infection by Trypanosoma cruzi: Lessons from Experimental Animals.Trypanosoma cruzi posttranscriptionally up-regulates and exploits cellular FLIP for inhibition of death-inducing signal.CD8(+) T cell-mediated immunity during Trypanosoma cruzi infection: a path for vaccine development?Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease.Tumor necrosis factor is a therapeutic target for immunological unbalance and cardiac abnormalities in chronic experimental Chagas' heart disease.Severity of chronic experimental Chagas' heart disease parallels tumour necrosis factor and nitric oxide levels in the serum: models of mild and severe disease.Novel cruzain inhibitors for the treatment of Chagas' disease.Chagasic patients are able to respond against a viral antigen from influenza virus.Elevated serum levels of macrophage migration inhibitory factor are associated with progressive chronic cardiomyopathy in patients with Chagas disease.Trypanosoma cruzi infection induces a global host cell response in cardiomyocytesEvaluating Chagas disease progression and cure through blood-derived biomarkers: a systematic review.A patient with erythema nodosus leprosum and Chagas cardiopathy: challenges in patient management and review of the literature.Evidence of reversible bradycardia and arrhythmias caused by immunogenic proteins secreted by T. cruzi in isolated rat heartsThe Trypanosoma cruzi satellite DNA OligoC-TesT and Trypanosoma cruzi kinetoplast DNA OligoC-TesT for diagnosis of Chagas disease: a multi-cohort comparative evaluation study.NADPH oxidase inhibition ameliorates Trypanosoma cruzi-induced myocarditis during Chagas disease.Mast cell function and death in Trypanosoma cruzi infection.Experimental Chemotherapy for Chagas Disease: A Morphological, Biochemical, and Proteomic Overview of Potential Trypanosoma cruzi Targets of Amidines Derivatives and Naphthoquinones.P47phox-/- mice are compromised in expansion and activation of CD8+ T cells and susceptible to Trypanosoma cruzi infection.Brain natriuretic peptide predicts survival in Chagas' disease more effectively than atrial natriuretic peptide.Clinical and epidemiological profile of elderly patients with Chagas disease followed between 2005-2013 by pharmaceutical care service in Ceará State, Northeastern Brazil.Early Regulation of Profibrotic Genes in Primary Human Cardiac Myocytes by Trypanosoma cruzi.Genomic and proteomic approaches for Chagas' disease: critical analysis of diagnostic methods.The effect of beta-blockade on myocardial remodelling in Chagas' cardiomyopathy.An overview of chagasic cardiomyopathy: pathogenic importance of oxidative stress.Current status and future prospects for a vaccine against American trypanosomiasis.
P2860
Q24194546-C9D6A5D0-D428-47CB-8B33-0FA83762421CQ24202908-4826B7B9-BEFE-42E1-BE22-39C05B0ED96AQ24235451-47010421-58C5-4C79-9DAA-7BF97C238E1FQ24815881-D9888C44-B73A-494A-8EBF-C69A58266AEEQ26471149-7AC2BD21-03BA-4DB7-8A0C-04FB9EF99CBCQ26829616-1BC84336-5B98-40C0-8B6E-637497D73F57Q28391025-E7E1AD96-7C2D-4D99-AA48-AAA4EA18EC60Q28542996-B42353D4-0288-4FF7-92A4-18209FFF1F9CQ28544692-7309490F-B8F2-4442-AFE2-F41680E1C2DAQ28550722-8C59C784-7792-4F75-9E5E-E427CC7B8FCAQ28553708-F170E82D-C217-442A-81F0-01F9A8B66B3FQ33358639-AADE6260-EAD1-44D8-A6F2-B23462E88CFEQ33587293-99C300CF-DC4E-4403-B804-B2514D1C6298Q33655042-E09E4C5A-BC36-4ED0-84E4-7D442247150BQ33817625-611E49E2-8A98-42E7-9D48-A606858FC289Q33902186-D71F3E19-146C-46D3-918A-A7B45131F179Q33911077-5E85ECE8-DF87-4B0C-9C9D-7800778B330FQ33914939-2D27B141-35A9-4708-9093-1D2A88DB69DDQ34016698-551488B8-AF8A-49A2-8F1A-5931484FECD5Q34032964-B14A04A0-020C-4F16-8707-753B94391BF1Q34040573-7CD94231-4BC5-4E4A-888E-750F31542085Q34276214-4EC8AAD7-D764-4013-92A9-0E703653EC86Q34392873-077145A8-4F54-4FBF-A44F-17061E07A63DQ34603215-748DE9E4-A3F5-49B4-9FB2-D6677AA36D3CQ34931802-46453DD2-F305-4A05-8BD7-CCD7EDE172C9Q34992879-157B4B36-B9A5-4843-AC49-DA3769F335EDQ35031953-0B5E1FF3-8A3F-41E3-9932-620AF95CA01AQ35043895-E8C27288-C5A4-4A78-83B7-456E1B07EB67Q35083540-0B0CB020-FD9C-4572-970E-30E41EC0EFB9Q35230292-15B46F7B-5714-4DF2-A440-FA57AC8741E7Q35235793-BB71DC1F-381A-4001-BB82-CA03D8797BFCQ35367533-13AFE115-0B7F-4220-8FD4-21BC33317058Q35488467-4AB79C81-AE1D-4BB3-AAC9-D13C6A290B7CQ35583849-833746D4-7E34-4D39-BA73-992A3B797AD1Q35617429-5F04063E-392C-4394-BB7B-3472C6F70B8CQ35895021-16965DFC-CFB6-4106-B5E7-AC70F124101FQ36192695-8CE0961E-3257-4616-A37C-6862584BC909Q36223002-A3C9FCFE-14DC-4D85-8835-6E1974254508Q36338129-9A91DC5F-86BA-462B-95AC-63648325A6A7Q36350576-94D986F5-C6E6-4220-8203-A9DD6835E4FE
P2860
Pathophysiology of the heart in Chagas' disease: current status and new developments.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Pathophysiology of the heart in Chagas' disease: current status and new developments.
@ast
Pathophysiology of the heart in Chagas' disease: current status and new developments.
@en
type
label
Pathophysiology of the heart in Chagas' disease: current status and new developments.
@ast
Pathophysiology of the heart in Chagas' disease: current status and new developments.
@en
prefLabel
Pathophysiology of the heart in Chagas' disease: current status and new developments.
@ast
Pathophysiology of the heart in Chagas' disease: current status and new developments.
@en
P50
P1476
Pathophysiology of the heart in Chagas' disease: current status and new developments.
@en
P2093
Luiz Alberto Benvenuti
P304
P356
10.1016/S0008-6363(03)00361-4
P577
2003-10-01T00:00:00Z